secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-09-02T20:32:39+00:00
Accession:  0001213900-26-096743
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 Biolabs furnishes Sept 2026 investor presentation; no financial detail disclosed
--------------------------------------------------------------------------------

- 20/20 Biolabs (AIDX) furnished an investor presentation, dated September 2026, for use in a Sept 2, 2026 investor webinar.
- Presentation text included in the exhibit contains only a cover slide; no revenue, EPS, pipeline, or guidance figures were provided.
- CEO Jonathan Cohen signed the 8-K; no operational or financial updates were disclosed in the filing body or exhibit.
- Material news content could not be extracted from the available exhibit text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026096743/0001213900-26-096743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026096743/ea0304455-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-096743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer